- Home
- LXRX vs VOR Comparison
LXRX vs VOR Comparison
Compare LXRX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | VOR |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 1.1B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXRX | VOR |
|---|---|---|
| Price | $1.60 | $19.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $4.55 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.0M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.10 | $6.50 |
| 52 Week High | $2.68 | $28.66 |
Technical Indicators
Market Signals| Indicator | LXRX | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 47.36 |
| Support Level | $1.50 | $17.35 |
| Resistance Level | $1.81 | $20.11 |
| Average True Range (ATR) | 0.07 | 1.15 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 27.20 | 53.76 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.